Lista de obras -

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect - Yes

artículo científico publicado en 2020

Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumab

artículo científico publicado en 2019

An observational study of alemtuzumab following fingolimod for multiple sclerosis.

scientific article published on 10 January 2017

Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis

artículo científico publicado en 2010

Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation

scientific article published on 19 April 2019

Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients

artículo científico publicado en 2011

Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial

artículo científico publicado en 2002

Application of "Mentzer's PML case definition" to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance

artículo científico publicado en 2020

Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy

artículo científico publicado en 2017

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

artículo científico publicado en 2018

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis

artículo científico publicado en 2017

Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity

artículo científico publicado en 2007

Blood platelet RNA enables the detection of multiple sclerosis

artículo científico publicado en 2020

Body fluid biomarkers for multiple sclerosis--the long road to clinical application

artículo científico

COVID-19 in multiple sclerosis: The Dutch experience

artículo científico publicado en 2020

CSF examination still has value in the diagnosis of MS - NO

artículo científico publicado en 2016

Cannabinoids and immune function

scientific article published on 01 August 2003

Cannabinoids in multiple sclerosis: do they have a therapeutic role?

artículo científico publicado en 2004

Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.

artículo científico publicado en 2017

Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables

artículo científico publicado en 2014

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.

artículo científico publicado en 2017

Chronic lymphocytic inflammation with Pontine perivascular enhancement responsive to steroids and fatal B-cell lymphoma--reply

artículo científico publicado en 2013

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis

artículo científico publicado en 2010

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

artículo científico publicado en 2012

Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance

scientific article published on 20 June 2020

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.

artículo científico publicado en 2017

Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis

artículo científico publicado en 2017

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML

artículo científico publicado en 2016

Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies

artículo científico publicado en 2011

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis

artículo científico publicado en 2018

Current trials in multiple sclerosis: established evidence and future hopes

artículo científico publicado en 2005

Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.

artículo científico publicado en 2003

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients

artículo científico publicado en 2016

Deep grey matter volume loss drives disability worsening in multiple sclerosis.

artículo científico publicado en 2018

Determinants of interferon β efficacy in patients with multiple sclerosis

artículo científico publicado en 2011

Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

artículo científico publicado en 2014

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients

artículo científico publicado en 2015

Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients

Differential effect of drug interference in immunogenicity assays

artículo científico publicado en 2011

Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring

scientific article published on 27 March 2019

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

artículo científico publicado en 2017

Drug interference in immunogenicity assays depends on valency

artículo científico publicado en 2013

Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases

artículo científico publicado en 2016

Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial

artículo científico

Emerging safety issues in alemtuzumab-treated MS patients

artículo científico publicado en 2019

Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.

artículo científico publicado en 2005

Fatal B-cell lymphoma following chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids

scientific article published on 01 July 2013

Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS

artículo científico publicado en 2017

Glutamate inhibition in MS: the neuroprotective properties of riluzole

artículo científico publicado en 2005

Gray matter networks and cognitive impairment in multiple sclerosis

artículo científico publicado en 2018

HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis

artículo científico publicado en 2009

Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature

artículo científico publicado en 2014

IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis

artículo científico publicado en 2011

Imaging of meningeal inflammation should become part of the routine MRI protocol - No

artículo científico publicado en 2018

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.

artículo científico publicado en 2018

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

artículo científico publicado en 2017

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?

artículo científico publicado en 2019

Infusion-related events during natalizumab: No need for post-infusion monitoring

scientific article published on 25 June 2019

Interferon beta in multiple sclerosis: predicting response at an early stage

artículo científico publicado en 2008

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

artículo científico publicado en 2015

Low JC virus antibody index during natalizumab treatment less safe than assumed?

artículo científico publicado en 2015

MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.

artículo científico publicado en 2015

MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance

artículo científico publicado en 2016

MRI pattern in asymptomatic natalizumab-associated PML.

artículo científico publicado en 2014

Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability

artículo científico publicado en 2014

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody

artículo científico publicado en 2011

Microcystic macular oedema confirmed, but not specific for multiple sclerosis

artículo científico publicado en 2012

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab

artículo científico publicado en 2020

Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels

artículo científico publicado en 2004

Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?

artículo científico publicado en 2017

Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis

artículo científico publicado en 2015

N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis

artículo científico publicado en 2014

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

artículo científico publicado en 2010

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

scientific article published on 19 December 2011

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations

artículo científico publicado en 2016

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

artículo científico publicado en 2007

Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?

scientific article published on 01 June 2006

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

artículo científico publicado en 2016

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients

scholarly article by Claire Bridel published in January 2018

Oral treatment for multiple sclerosis

artículo científico publicado en 2011

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

artículo científico publicado en 2013

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate

artículo científico publicado en 2015

Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort

article

Personalized extended interval dosing of natalizumab in MS- a prospective multicenter trial

artículo científico publicado en 2020

Pharmacodynamic assessment of cell-bound natalizumab on PBMC samples stored in liquid nitrogen

scientific article published on 12 July 2019

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

artículo científico publicado en 2008

Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications

scientific article published on 23 November 2020

Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases

artículo científico publicado en 2016

Plasma proteome in multiple sclerosis disease progression

artículo científico publicado en 2019

Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true?

scientific article published on 07 March 2014

Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein

artículo científico publicado en 2012

Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?

artículo científico publicado en 2013

Quantification of amyloid-beta 40 in cerebrospinal fluid

artículo científico publicado en 2009

Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a

artículo científico publicado en 2019

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

artículo científico publicado en 2010

Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS.

artículo científico publicado en 2017

Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

artículo científico publicado en 2017

Response to letter 'Lymphocyte counts and the risk of COVID-19 in people with MS'

artículo científico publicado en 2020

Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.

artículo científico publicado en 2017

Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients

artículo científico publicado en 2013

Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy

artículo científico publicado en 2019

Should CLIPPERS be considered a Prelymphoma state or a new Inflammatory disease

artículo científico publicado en 2013

Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS ⬇️

artículo científico publicado el 5 de octubre de 2010

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients

artículo científico publicado en 2017

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

artículo científico publicado en 2010

T lymphocytes impair P-glycoprotein function during neuroinflammation.

artículo científico publicado en 2009

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy

artículo científico publicado en 2013

The effect of prolonged natalizumab treatment on anxiety and safety in JC virus-seropositive MS patients; a follow-up study

artículo científico publicado en 2014

The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA.

artículo científico publicado en 2013

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

artículo científico publicado en 2017

The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms

artículo científico publicado en 2019

The physiological variation of the retinal nerve fiber layer thickness and macular volume in humans as assessed by spectral domain-optical coherence tomography

artículo científico publicado en 2012

The plasma peptides of Alzheimer's disease

artículo científico publicado en 2021

The plasma peptides of breast versus ovarian cancer

artículo científico publicado en 2019

The plasma peptides of ovarian cancer

scholarly article by Jaimie Dufresne et al published 2018 in Clinical Proteomics

The plasma peptidome

scholarly article by Jaimie Dufresne published in January 2018

The sequence of structural, functional and cognitive changes in multiple sclerosis

artículo científico publicado en 2020

The therapeutic value of cannabinoids in MS: real or imaginary?

scientific article published on 01 August 2004

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

artículo científico publicado en 2009

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study

artículo científico publicado en 2018

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study

scientific article published on 03 May 2016

Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

scientific article published on 02 April 2020

Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis

artículo científico publicado en 2015

What explains gray matter atrophy in long-standing multiple sclerosis?

artículo científico publicado en 2014

gMS-Classifier1 does not predict disability progression in multiple sclerosis.

artículo científico publicado en 2018

Lista de obras de

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect - Yes

Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumab

An observational study of alemtuzumab following fingolimod for multiple sclerosis.

Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis

Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation

Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients

Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial

Application of "Mentzer's PML case definition" to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance

Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis

Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity

Blood platelet RNA enables the detection of multiple sclerosis

Body fluid biomarkers for multiple sclerosis--the long road to clinical application

COVID-19 in multiple sclerosis: The Dutch experience

CSF examination still has value in the diagnosis of MS - NO

Cannabinoids and immune function

Cannabinoids in multiple sclerosis: do they have a therapeutic role?

Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.

Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.

Chronic lymphocytic inflammation with Pontine perivascular enhancement responsive to steroids and fatal B-cell lymphoma--reply

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.

Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML

Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis

Current trials in multiple sclerosis: established evidence and future hopes

Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients

Deep grey matter volume loss drives disability worsening in multiple sclerosis.

Determinants of interferon β efficacy in patients with multiple sclerosis

Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients

Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients

Differential effect of drug interference in immunogenicity assays

Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Drug interference in immunogenicity assays depends on valency

Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases

Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial

Emerging safety issues in alemtuzumab-treated MS patients

Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.

Fatal B-cell lymphoma following chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids

Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS

Glutamate inhibition in MS: the neuroprotective properties of riluzole

Gray matter networks and cognitive impairment in multiple sclerosis

HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis

Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature

IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis

Imaging of meningeal inflammation should become part of the routine MRI protocol - No

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?

Infusion-related events during natalizumab: No need for post-infusion monitoring

Interferon beta in multiple sclerosis: predicting response at an early stage

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

Low JC virus antibody index during natalizumab treatment less safe than assumed?

MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.

MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance

MRI pattern in asymptomatic natalizumab-associated PML.

Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody

Microcystic macular oedema confirmed, but not specific for multiple sclerosis

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab

Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels

Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?

Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis

N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients